Neurizon

Governance

Updates

Announcements

Home

Space Grotesk

upload.jpg

Stockhead Article

Neurizon was recently featured in this article by Stockhead. 

Managing director and CEO Dr Michael Thurn said the results provided compelling evidence that NUZ-001 and its sulfone metabolite not only effectively penetrate the BBB but do so at concentrations that are proven to reverse pathological TDP-43 aggregation in vitro.

“This new data provides strong translational validation for our mechanism and reinforces the potential of NUZ-001 as a transformative disease-modifying therapy for ALS,” he said.

“With these findings, we are more determined than ever to deliver a therapy that precisely targets the underlying pathology driving this devastating disease, supporting the accelerated advancement of NUZ-001."

Stockhead: Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential